National
U.S. House approves defense bill with anti-gay provisions
Bill reaffirms DOMA, could disrupt ‘Don’t Ask’ repeal
The U.S. House approved on Thursday major Pentagon budget legislation that includes anti-gay language that could disrupt “Don’t Ask, Don’t Tell” repeal and would reaffirm the Defense of Marriage Act.
By a vote of 322-96, the Republican-controlled House approved the fiscal year 2012 defense authorization bill after three days of debate that discussed continued military operations in Afghanistan, funding for next-generation military programs and increased pay rates for U.S. troops.
Among the many provisions of the defense authorization bill is anti-gay language that the House Armed Services Committee inserted upon consideration of the legislation.
The most high-profile anti-gay provision — offered as an amendment by Rep. Duncan Hunter (R-Calif.) — is language that would expand the certification requirement needed for repeal to include the four military service chiefs. Such a provision would complicate the repeal process established by the law signed in December, which would implement open service after 60 days pass following certification from the president, the defense secretary and the chair of the Joint Chiefs of Staff.
Another provision, offered as an amendment by Rep. Vicky Hartzler (R-Mo.), reaffirms that the Defense Department and its regulations are subject to the Defense of Marriage Act, which prohibits federal recognition of same-sex marriage.
Yet another provision — offered as an amendment by Rep. W. Todd Akin (R-Mo) — prohibits military facilities for being used for same-sex marriage ceremonies, even in states where same-sex marriage is legal, and prevents military chaplains from presiding over same-sex marriages in their official capacities. The language would expand the federal restrictions on same-sex marriage beyond what DOMA already imposes.
Laura Murphy, director of the ACLU Washington Legislative Office, expressed concerns over passage of the legislation — particularly for the inclusion of a provision authorizing worldwide war against terrorism suspects and nations suspected of supporting them — in addition to objecting to the provision that would complicate “Don’t Ask, Don’t Tell” repeal.
“Trying to throw a roadblock up to derail ‘Don’t Ask, Don’t Tell’ repeal at this point is a desperate attempt to postpone the inevitable,” Murphy said. “For nearly 20 years, lesbian, gay and bisexual service members have been forced to hide who they are and who they love in order to serve their country. It was with the will of the president, the uniformed and civilian leadership of the military and Congress itself that ‘Don’t Ask, Don’t Tell’ was repealed and its implementation will continue to move forward successfully despite the attempts by some House members to disrupt it.”
A number of lawmakers who supported “Don’t Ask, Don’t Tell” repeal last year voted in favor of the defense authorization bill despite the anti-gay language. On the House floor, some pro-repeal lawmakers said they were casting affirmative votes because they said they think the bill as whole is good for the U.S. armed forces.
On Tuesday, Rep. Susan Davis (D-Calif.), ranking Democrat on the House Armed Services personnel committee, objected to the language in the bill related to “Don’t Ask, Don’t Tell” as she expressed support for the legislation as a whole.
“While there are many good provisions in this bill, I must raise my extreme disappointment with several sections that were included by the majority that seek to delay and prevent gays and lesbians from serving in uniform,” Davis said. “One of the liberties that we as Americans hold dear is that we are all created equal. These individuals should be entitled to serve their Nation in uniform and should not be denied the opportunity.”
House Minority Leader Nancy Pelosi (D-Calif.) was also among the “Don’t Ask, Don’t Tell” repeal supporters who voted in favor of the defense authorization bill.
Drew Hammill, a Pelosi spokesperson, said the Democratic leader voted for the defense authorization bill despite the “Don’t Ask, Don’t Tell” language because she believes this provision won’t ultimately make it to the president’s desk.
“Leader Pelosi strongly opposes the [‘Don’t Ask, Don’t Tell’] language in the [defense] Authorization bill but believes the provisions concerning [‘Don’t Ask, Don’t Tell’] repeal will be removed in conference,” Hammill said. “If these provisions remain intact and are an obstacle to [‘Don’t Ask, Don’t Tell’] repeal implementation, she believes President Obama should veto the legislation.”
But each of the four openly gay members of Congress — Reps. Barney Frank (D-Mass.), Tammy Baldwin (D-Wis.), Jared Polis (D-Colo.) and David Cicilline (D-R.I.) — were among the among the 96 “no” votes on the legislation.
Although the House approved the defense authorization bill with anti-gay language, passing such a measure into law would be challenging because the Democratic-controlled Senate would have to agree to the anti-gay language during conference negotiations.
Aubrey Sarvis, executive director of the Servicemembers Legal Defense Network, said his organization is looking to the Senate to ensure the anti-gay provisions won’t appear in the final version of the defense authorization bill.
“The opposition may well believe they won the day in the House, simply outnumbering repeal advocates,” Sarvis said. “But this fight is far from over. We must look to repeal supporters in the Senate, where the defense bill will be taken up next and where we are better positioned than in the House. We need to beat back this harmful language and make sure it does not survive in conference committee.”
Another roadblock for the anti-gay language is President Obama, who would have to sign the provisions into law as part of the larger measure for them to enacted. The White House issued a Statement of Administration Policy earlier this week denouncing the provisions related to “Don’t Ask, Don’t Tell” and DOMA — although stopped short of threatening to veto the bill over this language.
Moreover, the certification expansion for “Don’t Ask, Don’t Tell” repeal may well be a moot point even if the legislation reaches the president’s desk. Defense officials have testified that certification for repeal could happen mid-summer, and the final version of the defense bill likely will not reach the president’s desk until after that time, rendering the provision useless.
Alex Nicholson, executive director of Servicemembers United, expressed skepticism about the anti-gay measures becoming law or thwarting “Don’t Ask, Don’t Tell” repeal.
“The passage of the defense authorization bill with these hostile amendments included comes as no surprise, and it should not become a cause for concern as long as our allies in the Senate and the president all stand strong and refuse to support a defense bill containing these amendments,” he said. “These amendments were nothing short of a waste of time by lawmakers who were sent to Washington to do serious business and a waste of taxpayer money. The Pentagon, the president, and the American people have made it abundantly clear — we are moving forward and building a stronger military free of unnecessary discrimination.”
No attempt was made on the House floor to strip the defense authorization bill of its anti-gay language. Del. Eleanor Holmes Norton (D-D.C.) had intended to offer an amendment to remove the language related to “Don’t Ask, Don’t Tell,” according to the Rules Committee website, but never offered the measure. Kezmiche Atterbury, a Norton spokesperson, said her boss “withdrew her amendment for tactical reasons.”
Informed sources said House Democratic leaders offered those who worked last year to repeal “Don’t Ask, Don’t Tell” repeal the opportunity for an amendment on the floor to eliminate the language in the defense authorization bill related to certification expansion.
However, the five major repeal organizations — the Human Rights Campaign, Servicemembers Legal Defense Network, Third Way, Servicemembers United and the Center for American Progress — agreed to decline the opportunity for the amendment.
According to sources, repeal advocates believed such a amendment would likely fail and could pick up support from moderate House Democrats. A defeat on the House floor, advocates believed, would increase the chances of the Senate adopting the certification expansion language.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
